Asciminib in chronic myeloid leukemia

被引:3
作者
Assanto, Giovanni Manfredi [1 ]
Scalzulli, Emilia [1 ]
Breccia, Massimo [1 ,2 ]
机构
[1] Az Policlin Umberto I Sapienza Univ, Dept Translat & Precis Med, Hematol, Rome, Italy
[2] Sapienza Univ, Dept Translat & Precis Med, Hematol, Via Benevento 6, I-00161 Rome, Italy
关键词
Asciminib; Chronic myeloid leukemia; BCR-ABL kinase inhibitors; STAMP (specifically; targeting the ABL myristoyl pocket) inhibitors; Hematologic malignancies; T315I mutation; IMATINIB-RESISTANT; CHRONIC-PHASE; FOLLOW-UP; DASATINIB;
D O I
10.1358/dot.2022.58.10.3441853
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the fact that, in the last years, life expectancy of chronic myeloid leukemia (CML) patients has reached that of the normal population, a significant propor-tion of CML patients is likely to fail treatment with first-or second-generation tyrosine kinase inhibitors (TKIs). Failure to first-line treatment is commonly due to molecular resistance or unbearable toxicity. New specific compounds are tested in this setting to fulfill this unmet clinical need in CML; of these, asciminib has shown efficacy based on allosteric inhibition which allows to overcome resistance and off-target toxicity. This review aims to cover how asciminib will change the therapeutic scenario of CML, highlight-ing its mechanism of action, pharmacokinetics, effi-cacy and toxicity. Asciminib will be a possible option as third-line therapy for patients carrying resistant mutations, such as T315I, and/or not eligible for treat-ment with other TKIs.
引用
收藏
页码:479 / 489
页数:11
相关论文
共 35 条
  • [1] [Anonymous], SCEMBL ASC TABL OR U
  • [2] [Anonymous], 2022, NOV SCEMBL NOV MECH
  • [3] [Anonymous], PHARM STUD ASC SUBJ
  • [4] How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)
    Breccia, Massimo
    Olimpieri, Pier Paolo
    Olimpieri, Odoardo
    Pane, Fabrizio
    Iurlo, Alessandra
    Foggi, Paolo
    Cirilli, Alessia
    Colatrella, Antonietta
    Cuomo, Marcello
    Gozzo, Lucia
    Summa, Valentina
    Corradini, Paolo
    Russo, Pierluigi
    [J]. CANCER MEDICINE, 2020, 9 (12): : 4160 - 4165
  • [5] Cortes J., 2019, HEMASPHERE, V3, P397, DOI DOI 10.1097/01.HS9.0000561812.22500.D8
  • [6] Third-line therapy for chronic myeloid leukemia: current status and future directions
    Cortes, Jorge
    Lang, Fabian
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [7] Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial
    Cortes, Jorge E.
    Hughes, Timothy P.
    Mauro, Michael J.
    Hochhaus, Andreas
    Rea, Delphine
    Goh, Yeow Tee
    Janssen, Jeroen
    Steegmann, Juan Luis
    Heinrich, Michael C.
    Talpaz, Moshe
    Etienne, Gabriel
    Breccia, Massimo
    Deininger, Michael W.
    le Coutre, Philipp D.
    Lang, Fabian
    Aimone, Paola
    Polydoros, Fotis
    Cacciatore, Silvia
    Stenson, Laura
    Kim, Dong-Wook
    [J]. BLOOD, 2020, 136
  • [8] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Haluska, Frank G.
    Guilhot, Francois
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Shah, Neil P.
    Kantarjian, Hagop M.
    [J]. BLOOD, 2018, 132 (04) : 393 - 404
  • [9] Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    Cortes, Jorge E.
    Gambacorti-Passerini, Carlo
    Deininger, Michael W.
    Mauro, Michael J.
    Chuah, Charles
    Kim, Dong-Wook
    Dyagil, Irina
    Glushko, Nataliia
    Milojkovic, Dragana
    le Coutre, Philipp
    Garcia-Gutierrez, Valentin
    Reilly, Laurence
    Jeynes-Ellis, Allison
    Leip, Eric
    Bardy-Bouxin, Nathalie
    Hochhaus, Andreas
    Brummendorf, Tim H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 231 - +
  • [10] Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
    Cortes, Jorge E.
    Saglio, Giuseppe
    Kantarjian, Hagop M.
    Baccarani, Michele
    Mayer, Jiri
    Boque, Concepcion
    Shah, Neil P.
    Chuah, Charles
    Casanova, Luis
    Bradley-Garelik, Brigid
    Manos, George
    Hochhaus, Andreas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) : 2333 - U54